Millie
your market intelligence analyst
Search Results
Edit Save
940 results
Labiotech.eu (EU) 09/23/2020 04:52
Anyone investing in public biotech companies will find it challenging to answer the key question: does this company have a good chance to create real value? Medical breakthroughs can result in huge revenues, but being the first to develop and commercialize technologies based on cutting-edge research inherently comes with a high risk of failure.
Labiotech.eu (EU) 09/23/2020 04:00
Immune cell monitoring is imperative for almost any clinical study. The problem: Current procedures require viable cells, a demand often torpedoed by sample logistics. What do cancer, autoimmune diseases, and have in common? Hint: Think of immune cells. In immuno-oncology, therapeutic approaches provoke a targeted immune response against the tumor. In autoimmune diseases, a dysregulated response of the immune system attacks the body’s cells. In Covid-19, severe complications are attributed to immune cell activity rather than to the toxicity of the virus. Monitoring the immune cell status is, therefore, essential to study these conditions. In clinical trials, monitoring the activity of immune cells and the changing composition of various imm.
Labiotech.eu (EU) 09/17/2020 08:28
3D printing has revolutionized manufacturing by reducing costs and giving designers and engineers immense flexibility. Could 3D bioprinting do the same for biotechnology? The 3D bioprinting field is still quite young, but it is developing rapidly. In fact, the 3D bioprinting market is expected to grow from €700M ($820M) in 2019 to a massive . With the interest of investors peaking, many companies in the field have recently taken strides forward in their technological development. Over the last decade, bioprinting has generated a lot of expectations, such as 3D printing organs for transplantation or . Such breakthroughs may still be far from reaching the market, but 3D bioprinting has been finding more and more uses in the biomedical field.
Labiotech.eu (EU) 09/16/2020 12:45
The recent founding of Modulus Therapeutics in the UK has highlighted an accelerating movement in cancer research that aims to attack solid tumors via their ‘comfort zone’, known as the tumor microenvironment. Cancer drugs in the market today generally fall into two broad camps: those that kill cancer cells directly, and those that boost the immune system’s natural ability to destroy cancer cells.
Labiotech.eu (EU) 09/16/2020 04:00
As a wave of Covid-19 infected the crew of a commercial fishing vessel, three sailors remained healthy. They may hold the key to answer one of the most important questions of the coronavirus pandemic: does infection with the virus protect against later re-infection? Sailors become accidental research subjects. The has left researchers quickly scrambling to understand the SARS-CoV-2 virus causing Covid-19. But ethical concerns make it difficult to experiment on human subjects and retrospective analyses of real-life outbreaks often remain as a last resort instead. One commercial fishing crew recently became the accidental focus of coronavirus research when the virus went rampant on their vessel. Some of the sailors remained healthy, and that t.
Labiotech.eu (EU) 09/14/2020 11:30
The Dutch startup Neogene Therapeutics has become the second T-cell therapy developer to raise a spectacularly large Series A round in Europe this year. The Series A round was co-led by the VC firms EcoR1 Capital, Syncona, and Jeito Capital. Neogene Therapeutics will use part of the €93M proceeds to advance its T-cell therapy immuno-oncology candidate into phase I clinical trials by 2022.
Labiotech.eu (EU) 09/14/2020 09:14
Funding is the lifeline of innovative ventures. In an increasingly uncertain environment, looking at the records of past investments can be essential for making sense of the future and getting closer to discovering what’s next for the life sciences industry. Exploring the differences between the two major groups of life sciences investors and the funding flow between their locations is essential for understanding the current global industry trends and getting the sense of the direction the life science space is heading in the years to come. We leveraged the to dive deep into two of the most influential life science markets in the world — the US and Europe — and discover emerging trends that will help understand the existing landscape and de.
Labiotech.eu (EU) 09/14/2020 04:00
As the Covid-19 pandemic rages, worries about rising antimicrobial resistance are increasing too. One company is preparing for future pandemics and antimicrobial resistance. The intentions of AiCuris as a company are unequivocal and can be determined simply by breaking down the company name: Ai = anti-infective and Curis refers to finding a cure. Emphasizing this tenet, while speaking about the current pandemic, Holger Zimmermann, Chief Executive Officer of AiCuris, said: “ In times like these, biotech and pharmaceutical companies have a great societal responsibility. We must ask ourselves how we can best help in such a situation. ”To this end – preparation for future pandemics and antimicrobial resistance – AiCuris, a leading company in a.
Labiotech.eu (EU) 09/10/2020 13:03
Genetic engineering is breaking new ground in the control of mosquito-borne diseases. However, a genetic engineering approach isn’t the only option, as many biotech companies aim to prove. As the global climate continues to warm, disease-spreading mosquitoes such as Aedes aegypti are expected to . This could result in explosive outbreaks of debilitating mosquito-borne infections such as dengue fever, Zika, and chikungunya. At the same time, some of the most effective control methods, chemical insecticides, are against insecticide resistance. The UK company Oxitec, owned by the US firm Third Security, is making big headlines lately for its efforts to prevent mosquito-borne infections. Last month, the company to launch the first US pilot stud.
Labiotech.eu (EU) 09/09/2020 04:06
Norway has not typically been an attractive region for biotech investors, so when Masha Strømme set up her own investment firm in 2008, she had to take a slightly different approach to investment. Masha Strømme and her husband, Dag Strømme, run a family office together called Paacs Invest in the Oslo area, which funds and mentors local early-stage biotech companies. Strømme started out as a scientist doing a PhD at the University of Oxford in genetics and neuroscience.
Labiotech.eu (EU) 09/09/2020 04:00
The crisis of antibiotic resistance is making the discovery and development of new antibiotics crucial, and companies are teaming up to tackle the growing challenge. But managing collaborative drug discovery data is tough, requiring many small biotechs to rethink how they share and manage their data for antimicrobial development. Antimicrobial resistance is on the rise. Worldwide, approximately people die from drug-resistant infections each year. According to the World Health Organization (WHO), if nothing is done to prevent it, this number could increase to deaths by 2050. So why has the situation escalated this much? The problem, explained Andrej Trauner, Project Manager in Discovery Research at Swiss biotech BioVersys, is that we have ta.
Labiotech.eu (EU) 09/08/2020 12:05
In recent times, an unexpectedly large number of investments have closed in biotech startups offering sustainable meat alternatives. Why are investors flocking to this field amid a raging pandemic? Traditional agriculture is a major polluter, especially in the case of meat production. The highest estimations place its share of global greenhouse gas emissions at . In an effort to meet the growing demand for sustainability, many biotech companies are developing less energy-intensive sources of protein via fermentation and plant products. In spite of the financial chaos resulting from the Covid-19 pandemic this year, big money has gone to biotech startups producing meat alternatives. In the US, the prime example is Impossible Foods, which gene.
Labiotech.eu (EU) 09/07/2020 06:00
CRISPR-Cas9 has taken the world by storm with the promise of making gene editing much easier and faster than ever before. But how does CRISPR actually work? How can biology research benefit from it? What will happen when we start using it to edit human DNA? And what’s the fight between its developers all about? CRISPR-Cas9 is one of the biggest discoveries of the 21st century. Since it was developed in 2012, this gene editing tool has revolutionized biology research, making it easier to study disease and faster to discover drugs. The technology is also significantly impacting the development of crops, foods, and industrial fermentation processes. But the one application that has made it famous is the modification of the human genome, which
Labiotech.eu (EU) 09/07/2020 04:10
Bioburden detection is one of the quality control measures required to ensure drug safety – and a possible bottleneck for product release. Most of the challenges of drug development are ticked off the list once the product has been launched. Others stay relevant throughout the product’s lifetime – for example, bioburden detection. Remarkably, bioburden detection is not only required for the final product but also for raw materials and process intermediates. Over the course of the production run, delays related to bioburden detection add up, creating a bottleneck both for patients waiting for their therapy and the pharma company to deliver to the market. Filter challenges. Bioburden can be defined as the number of microorganisms (bacteria, ye.
Labiotech.eu (EU) 09/03/2020 07:57
After years of drought, recent technological and clinical breakthroughs are causing research into chronic kidney disease treatments to resurge. is an incurable condition where the kidneys are damaged over time and gradually stop working properly. It usually overlaps with common age-related conditions such as cardiovascular disease and diabetes. In spite of a , there are still no effective treatments for chronic kidney disease. Current medications are limited to tackling the symptoms, which include swelling and blood in the urine. Even this much for patients suffering from multiple conditions and taking lots of different medications, which can further damage the kidneys. “ While many of the symptoms can be controlled successfully, in many ca.
Labiotech.eu (EU) 09/02/2020 03:46
For decades, Alzheimer’s disease research focused on a hypothesis that has increasingly been challenged. A team of scientists in Slovakia has been swimming against the tide since the beginning, going for an alternative approach that has only recently started gaining recognition. Research in Alzheimer’s disease has recently been plagued by intense disappointment. For over 25 years, the majority of scientists pursued the so-called amyloid-beta hypothesis — the initially compelling idea that the key driver behind the disease is the accumulation of plaques of the amyloid-beta protein in the brain. Billions of dollars were spent globally by the biopharma industry to develop therapies aimed at removing these plaques, in the hope that this would b.
Labiotech.eu (EU) 09/01/2020 09:35
Providers of microbiome therapies worldwide have been hit by pandemic restrictions on the harvest of stool samples. Though these measures are now loosening in France, key safety challenges remain for companies using fecal microbiota. — procedures where healthy individuals donate their gut microbes to a patient — have changed how we treat deadly Clostridium difficile infections. Unlike current treatments such as antibiotics, this method is designed to restore the balance of the , and prevent the recurrence of the infection. Fecal microbiota transplants require a supply of healthy donor stool. This year, stool supplies came under threat as the Covid-19 pandemic arrived. In March, the French regulator of healthcare products, the ANSM, that any.
Labiotech.eu (EU) 08/31/2020 05:14
Despite their ability to create matter out of thin air, algae and cyanobacteria have long been neglected by the biotech industry. Recently, however, they have started to gain traction in new market niches. In the center of Paris, just across from old laboratory, Pierre Crozet, Associate Professor at Sorbonne University, studies photosynthesis. His research focuses on making microalgae easier to engineer and thus more appealing to the industry. “[Microalgae] are photosynthetic, and quite efficient at it, but require much less space or nutrients than land plants, ” he told me. The idea that new technologies should serve sustainability has started taking root in society. Using photosynthetic microbes for biotech applications appears to be a no.

Financial Services

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Political Entities

Sources

Strategic Scenarios

Trends

Hints:

  • Actions
    • Bookmark and Share: Allows you to Bookmark the page for easy future retrieval and sharing with colleagues
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • Previous Versions: Only shown if essentially the same document has been republished
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Save" button to the right of the search box. 

Click here for more info on Search Results.